← Back to Search

Culturally Tailored Interventions for Alzheimer's Disease

N/A

Recruiting

Led By Spero Manson, PhD

Research Sponsored by University of Colorado, Denver

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 40 or older

Has cognitive and decisional capacity to consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Awards & highlights

Study Summary

This trial will study whether written or video-based materials are more effective in recruiting AI/AN individuals into AD and PM research, and will also create a registry of AI/AN individuals who are willing to be contacted for future research opportunities.

Who is the study for?

This trial is for American Indian or Alaska Native individuals who are 40 years or older, can speak and read English, and have the ability to make decisions about their participation. It's not suitable for those with vision or hearing impairments that prevent them from reading a brochure or watching a video.Check my eligibility

What is being tested?

The study is comparing two methods of providing information: one group will receive a culturally tailored video while another will get a brochure. The goal is to see which method is more effective in recruiting participants into Alzheimer's disease research among native populations.See study design

What are the potential side effects?

Since this trial involves educational materials rather than medical treatments, there are no direct physical side effects expected from participating in this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 40 years old or older.

Select...

I am mentally capable of understanding and consenting to treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

AD-PM Module Completion

Cohort Enrollment Questionnaire

Secondary outcome measures

Alzheimer's Disease (AD) Knowledge Scale

Attitudes about Precision Medicine self-report survey

Orthogonal Cultural Identification Scale

+2 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Culturally tailored video intervention groupExperimental Treatment1 Intervention

Participants will view a short 5-minute culturally-tailored video.

Group II: Culturally tailored brochure intervention groupExperimental Treatment1 Intervention

Participants will read a culturally-tailored educational brochure on Alzheimer's disease and Precision Medicine.

Group III: Non-tailored control groupActive Control1 Intervention

Participates will read the standard Alzheimer's disease and Precision Medicine brochure with standard text-based content NOT specifically tailored for AI/ANs.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Missouri Breaks Industries Research, Inc.OTHER

7 Previous Clinical Trials

1,656 Total Patients Enrolled

Washington State UniversityOTHER

101 Previous Clinical Trials

56,213 Total Patients Enrolled

University of Colorado, DenverLead Sponsor

1,738 Previous Clinical Trials

2,149,025 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What results are researchers expecting from this investigation?

"The primary outcome is AD-PM Module Completion, measured over a Baseline time frame. Secondary endpoints encompass the Alzheimer's disease (AD) Knowledge Scale which comprises of 30 true/false items on topics such as risk factors and management; Willingness to Participate in Research Questionnaire that reveals participants' receptiveness towards hypothetical research projects related to dementia and Precision Medicine through 4 vignettes scored between 1 - 4; and Orthogonal Cultural Identification Scale with scores ranging from 1 - 4 reflecting individuals' cultural identity when it comes to family and community interactions."

Answered by AI

Is my participation in this medical experiment allowed?

"This investigation requires 501 individuals of age 40 or older, up to 100 years old, with Alzheimer's disease. In addition, all participants must possess the mental capacity to offer informed consent."

Answered by AI

Are the age restrictions for this clinical trial expansive enough to include those over 50?

"Patients aged 40 and up to 100 years old are welcome to apply for this clinical trial."

Answered by AI

Are there currently any open slots in this experiment?

"Affirmative. According to clinicaltrials.gov, this medical investigation is still recruiting patients and had its initial posting on May 1st 2021 with the most recent update occurring August 12th 2022. The study requires 501 participants from a single location."

Answered by AI

How many participants have enrolled in the research project thus far?

"Indeed, according to the clinicaltrials.gov database, this medical study is currently recruiting patients that meet their criteria. The trial was published on May 1st 2021 and revised on August 12th 2022 with 501 volunteers needed from a single site."

Answered by AI

Recent research and studies

American Journal of Public HealthJournal

A Nationwide Population-based Study Identifying Health Disparities Between American Indians/alaska Natives and the General Populations Living in Select Urban Counties

Castor, Mei L., Michael S. Smyser, Maile M. Taualii, Alice N. Park, Shelley A. Lawson, and Ralph A. Forquera. 2006. “A Nationwide Population-based Study Identifying Health Disparities Between American Indians/alaska Natives and the General Populations Living in Select Urban Counties”. American Journal of Public Health. American Public Health Association. doi:10.2105/ajph.2004.053942.

NeurologyJournal

Race/ethnic Differences in AD Survival in US Alzheimer's Disease Centers

Mehta, K. M., K. Yaffe, E. J. Perez-Stable, A. Stewart, D. Barnes, B. F. Kurland, and B. L. Miller. 2007. “Race/ethnic Differences in AD Survival in US Alzheimer's Disease Centers”. Neurology. Ovid Technologies (Wolters Kluwer Health). doi:10.1212/01.wnl.0000285287.99923.3c.

clinicaltrials.govStudy

Alzheimer's Disease and Precision Medicine Research Among Native People

2021. "Alzheimer's Disease and Precision Medicine Research Among Native People". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03448601.

All > Alzheimer Disease > Alzheimers Disease